Confusing Regulatory Landscape in US Could Spur Caution Among Dx Test Developers | GenomeWeb
The US Food and Drug Administration’s intent to regulate in vitro diagnostic multivariate index assays has made genetic test developers more cautious, even before the agency codifies its goal.
Since the FDA expressed its desire last year to regulate IVDMIAs, genetic test developers have consistently criticized the agency’s approach for regulating laboratory-developed genetic tests as arbitrary, piecemeal, and a potential hindrance to innovation.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.